Related Experiment Video
Updated: May 28, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Parenteral Berberine vs Cisplatin- Loaded Lipid Nanoparticles - Development, Characterisation, Comparative Safety
Martin Manov1, Denitsa Stefanova1, Virginia Tzankova1
1Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Introduction:
Cholangiocarcinoma (CCA) is an aggressive and heterogeneous malignancy of the biliary tract with a poor prognosis. Berberine can be a therapeutic option with low toxicity, but its delivery remains challenging. Encapsulation in lipid nanoparticles offers a promising biocompatible strategy to improve the delivery and safety of berberine.
Purpose:
This study aimed to develop, characterize berberine-loaded nanostructured lipid carriers (N-Ber) and evaluate their cytotoxicity in CCA cell models in comparison to a standard chemotherapeutic, cisplatin, in both free and nanoparticle-loaded form (N-Cis). The in vitro biocompatibility for potential parenteral delivery of the nanocarriers was a secondary goal of the work.
Methods:
Nanoparticles were prepared by solvent evaporation with Precirol 5 ATO and oleic acid as lipids and Tween 20 as a stabilizer and were characterized by DLS, morphology, encapsulation efficiency, and in vitro drug release at physiological (pH 7.4) and tumor-mimicking (pH 5.5) conditions. Cytotoxicity was evaluated in three CCA cell lines (TFK-1, EGI-1, and HuCCT1) using the MTT assay, while endothelial cells (Ea.hy926) and the hemolysis test in human erythrocytes were employed to evaluate safety.
Results:
N-Ber and N-Cis displayed mean sizes 159.5 nm and 146.7 nm, respectively, negative surface charge (-27.95 mV and -50.75 mV), and high encapsulation efficiencies (berberine: 88.8%; cisplatin: 95.8%). Both nanoformulations showed significantly altered dissolution profiles compared to the free drugs. Berberine showed potent cytotoxicity against all CCA cell lines (IC5 0 0.4-5.2 µM), comparable or superior to cisplatin (IC5 0 ≈ 10 µM) and these effects were preserved after nanoencapsulation. In contrast, N-Ber exhibited low toxicity towards endothelial cells and no relevant hemolytic activity (<5% hemolysis) at therapeutic concentrations, while N-Cis induced marked hemolysis at all tested doses.
Discussion:
N-Ber combines strong cytotoxicity in CCA cells with a favorable biocompatibility compared to N-Cis. The promising in vitro data warrant further in vivo evaluation.
